If the overuse of antibiotics continues, it is estimated that by 2050 the world will face an additional 10 million deaths due to antibiotic resistant infections at a cost of $100 trillion to the global economy.

Momentum Bioscience is developing a range of innovative diagnostic products to help combat antibiotic resistance and sepsis by providing early detection of the presence and absence of bloodstream infections.

90% of blood cultures are negative resulting in patients
frequently left on unnecessary antibiotics

EARLY CONFIRMATION OF NEGATIVE RESULTS CAN DRAMATICALLY REDUCE THE UNNECESSARY USE OF ANTIBIOTICS

tube-pos 10% Approximately 10% of blood culture samples submitted for microbiological testing are found to be positive.

tube-neg 90% 90% of samples are generally reported as negative after five days of incubation.

TRADITIONAL DIAGNOSTIC PRODUCTS TAKE UP TO FIVE DAYS TO PRODUCE RESULTS

calander 05

Patients are prescribed broad spectrum IV antibiotics without clear evidence of infection, to avoid the risk of delaying treatment.

MOMENTUM’S COGNITOR® PRODUCT (WITH PATENTED ETGA® TECHNOLOGY) PROVIDES NEGATIVE RESULTS IN ONE DAY

calander 01

Providing a negative result quickly means patients need not be prescribed with unnecessary antibiotics.

EARLY NEGATIVE RESULTS PROVIDE MANY BENEFITS

icon-01

LOWERING COSTS

icon-02

MORE EFFICIENT HOSPITALS

icon-03

Decreased antibiotic
associated disease

icon-04

Getting patients home
sooner

In 74% of cases, the physician changed treatment when
Cognitor® showed blood culture was negative.

Focused on Patients

About us

Our team is made up of experienced and talented individuals who are determined and passionate about combating antimicrobial resistance.

about
about
about
about
about

Founded in the UK to develop rapid tests for
critically-important clinical specimens

Founded in the UK to provide faster diagnostic assessment of patients suspected of bloodstream infections (BSI), a condition which can lead to deadly septic shock and requires accurate and immediate antibiotic therapy.

Our technology has the potential to uniquely provide the
information physicians need to manage the majority of their
blood culture patients

Technology

Unlike other rapid technologies ETGA® provides ultrasensitive, rapid and universal detection of all bacterial and fungal species and it only detects viable organisms.

etga_01

Specimen: Suspected of containing bacteria or fungi.

etga_02

Sample clean-up: Following sample lysis, residual enzymes outside the target micro-organisms are inactivated.

etga_03

Microbial lysis: Target micro-organisms are lysed. DNA-modifying enzymes, including DNA polymerase, are released.

etga_04

Substrate modification: The DNA-modifying enzymes are incubated with synthetic DNA substrate. This is then modified to create a template for PCR.

etga_05

PCR template:
This is amplified & measured using qPCR. If there are no micro-organisms present in the sample, the PCR target will not be created and no amplification will occur.

Leadership Team

Chairman -
Bill Moffitt, BS.

Chief Scientific Officer -
William Mullen PhD.

Chief Executive -
Sumi Thaker.

Consulting Chief Operating Officer -
Jim Thurlow, BSc

Head of R&D -
Matthew Crow, PhD.

Head of Operations -
John Hockley, BSc (Hons), PGDip

Investors

finance wales
longwall ventures
wren capitol logo

“Promote new, rapid diagnostics to cut unnecessary
use of antibiotics”
Recommendation 5, O’Neill report 2016-11-09

News

RESOURCES

USING COGNITOR® -
DEMONSTRATION VIDEO
& INSTRUCTIONS FOR USE

video1

Preparing Your Control

video2

Obtaining the Blood Culture Sample

video3

Blood Lysis

video4

Host Contaminant Removal Part 1

video5

Host Contaminant Removal Part 2

video6

Microbial Lysis

video7

Bead-Milling And Incubation**

video8

PCR Setup

video9

PCR & Assay Results

CONTACT MOMENTUM